Patients turn to 'gray market' for cheaper obesity drugs, but it's risky

Patients seeking more affordable obesity medications are increasingly turning to the gray market, where they purchase raw ingredients from China to prepare the drugs themselves. This trend raises significant concerns about safety and efficacy, as these unregulated sources can pose serious health risks. It's crucial for patients to understand the potential dangers involved in this approach, as the lack of oversight may lead to harmful consequences.